Drug General Information
Drug ID
D0Z9VY
Former ID
DCL000016
Drug Name
UCN-01
Synonyms
UCN; UCN01; Ucn 01; KRX-0601; KW-2401; UCN-02; (5s,6r,7r,9r,16r)-16-hydroxy-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one; 7-Hydroxystaurosporine; 7-hydroxystaurosporine (UCN-01)
Drug Type
Small molecular drug
Indication Non-small cell lung cancer [ICD10:C33-C34] Phase 2 [521597]
Therapeutic Class
Anticancer Agents
Company
Keryx BioPharma.
Structure
Download
2D MOL

3D MOL

Formula
C28H26N4O4
Canonical SMILES
CC12C(C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C5<br />3)C(NC6=O)O)NC)OC
InChI
1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1
InChIKey
PBCZSGKMGDDXIJ-HQCWYSJUSA-N
CAS Number
CAS 112953-11-4
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Serine/threonine-protein kinase Chk1 Target Info Inhibitor [535584], [537127], [537231], [537385], [537458]
KEGG Pathway Cell cycle
p53 signaling pathway
HTLV-I infection
Viral carcinogenesis
Pathway Interaction Database Fanconi anemia pathway
p73 transcription factor network
ATR signaling pathway
Circadian rhythm pathway
p53 pathway
Reactome Activation of ATR in response to replication stress
Processing of DNA double-strand break ends
Presynaptic phase of homologous DNA pairing and strand exchange
G2/M DNA damage checkpoint
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
WikiPathways DNA Damage Response
Signaling by SCF-KIT
ATM Signaling Pathway
Retinoblastoma (RB) in Cancer
Integrated Pancreatic Cancer Pathway
Prostate Cancer
Integrated Breast Cancer Pathway
Integrated Cancer pathway
Cell Cycle
Cell Cycle Checkpoints
miRNA Regulation of DNA Damage Response
References
Ref 521597ClinicalTrials.gov (NCT00082017) UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas. U.S. National Institutes of Health.
Ref 535584UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res. 2002 Oct 15;62(20):5743-8.
Ref 537127Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. Invest New Drugs. 2009 Mar 5.
Ref 537231CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol Cancer. 2009 Apr 16;8:24.
Ref 537385Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach. J Mol Graph Model. 2009 May 3.
Ref 537458The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem. 2009 Jun;9(5):550-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.